Striatal D2 receptors changes parallel the progression of Parkinson's disease (PD)

G. Pizzolato; A. Cagnin; D. Delibori; F. Bracco; M. Dam; L. Battistin; F. Chierichetti; G. Ferlin

Striatal D2 receptors changes parallel the progression of Parkinson's disease (PD)

G. Pizzolato, A. Cagnin, D. Delibori, F. Bracco, M. Dam, L. Battistin, F. Chierichetti, G. Ferlin

Istituto di Neuroriabilitazione Motoria San Camillo

Research output: Contribution to journal › Article › peer-review

Abstract

To investigate the relationship between D2 receptors changes and disease progression, we used ¹²³I-IBZM SPET to longitudinally assess striatal D2 receptors activity in 13 PD patients who, at baseline study, were in the early drug-naive stage of the disease (mean H-Y score: 1.7±0.6). Follow-up SPET was performed after 3.1±1.3 y (mean H-Y score: 2.1±0.7; mean daily dosage of L-Dopa: 425±136mg). Caudate EBZM uptake at the baseline study showed a significant correlation with the ensuing rate of progression of PD, measured by the H-Y annual score change (r=-0.66, p

Original language	English
Pages (from-to)	20
Number of pages	1
Journal	Italian Journal of Neurological Sciences
Volume	18
Issue number	4
Publication status	Published - 1997

ASJC Scopus subject areas

Neuroscience(all)
Clinical Neurology

Access to Document

Fingerprint Dive into the research topics of 'Striatal D2 receptors changes parallel the progression of Parkinson's disease (PD)'. Together they form a unique fingerprint.

Cite this

@article{415c8c95ce484b8c860ecd61b457f0b4,

title = "Striatal D2 receptors changes parallel the progression of Parkinson's disease (PD)",

abstract = "To investigate the relationship between D2 receptors changes and disease progression, we used 123I-IBZM SPET to longitudinally assess striatal D2 receptors activity in 13 PD patients who, at baseline study, were in the early drug-naive stage of the disease (mean H-Y score: 1.7±0.6). Follow-up SPET was performed after 3.1±1.3 y (mean H-Y score: 2.1±0.7; mean daily dosage of L-Dopa: 425±136mg). Caudate EBZM uptake at the baseline study showed a significant correlation with the ensuing rate of progression of PD, measured by the H-Y annual score change (r=-0.66, p",

author = "G. Pizzolato and A. Cagnin and D. Delibori and F. Bracco and M. Dam and L. Battistin and F. Chierichetti and G. Ferlin",

year = "1997",

language = "English",

volume = "18",

pages = "20",

journal = "Italian Journal of Neurological Sciences",

issn = "0392-0461",

publisher = "Springer Verlag",

number = "4",

}

TY - JOUR

T1 - Striatal D2 receptors changes parallel the progression of Parkinson's disease (PD)

AU - Pizzolato, G.

AU - Cagnin, A.

AU - Delibori, D.

AU - Bracco, F.

AU - Dam, M.

AU - Battistin, L.

AU - Chierichetti, F.

AU - Ferlin, G.

PY - 1997

Y1 - 1997

N2 - To investigate the relationship between D2 receptors changes and disease progression, we used 123I-IBZM SPET to longitudinally assess striatal D2 receptors activity in 13 PD patients who, at baseline study, were in the early drug-naive stage of the disease (mean H-Y score: 1.7±0.6). Follow-up SPET was performed after 3.1±1.3 y (mean H-Y score: 2.1±0.7; mean daily dosage of L-Dopa: 425±136mg). Caudate EBZM uptake at the baseline study showed a significant correlation with the ensuing rate of progression of PD, measured by the H-Y annual score change (r=-0.66, p

AB - To investigate the relationship between D2 receptors changes and disease progression, we used 123I-IBZM SPET to longitudinally assess striatal D2 receptors activity in 13 PD patients who, at baseline study, were in the early drug-naive stage of the disease (mean H-Y score: 1.7±0.6). Follow-up SPET was performed after 3.1±1.3 y (mean H-Y score: 2.1±0.7; mean daily dosage of L-Dopa: 425±136mg). Caudate EBZM uptake at the baseline study showed a significant correlation with the ensuing rate of progression of PD, measured by the H-Y annual score change (r=-0.66, p

UR - http://www.scopus.com/inward/record.url?scp=33746374460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746374460&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33746374460

VL - 18

SP - 20

JO - Italian Journal of Neurological Sciences

JF - Italian Journal of Neurological Sciences

SN - 0392-0461

IS - 4

ER -